Sugi Predict

Sugi Predict / Compounds / SCHEMBL3964630

SCHEMBL3964630

SCHEMBL3964630

Cc1ccc(S(=O)(=O)N[C@H](C(=O)O)C(C)C)cc1

nearest known ligand 0.91

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ MMP9 P14780 13/20 0.91
▸ MMP2 P08253 13/20 0.91
▸ MMP3 P08254 10/20 0.91
▸ MMP13 P45452 10/20 0.91
▸ MMP1 P03956 9/20 0.91
▸ MMP7 P09237 9/20 0.91
▸ ADAMTS4 O75173 3/20 0.72
▸ SLC1A3 P43003 1/20 0.72
▸ SLC1A2 P43004 1/20 0.72
▸ SLC1A1 P43005 1/20 0.72
▸ MMP14 P50281 1/20 0.68
▸ MMP8 P22894 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4588942 1.00 MMP9 (0.91) MMP9MMP2MMP3MMP13MMP1
SCHEMBL6446613 1.00 MMP9 (0.91) MMP9MMP2MMP3MMP13MMP1
SCHEMBL7870625 0.95 MMP2 (1.00) MMP9MMP2MMP3MMP13MMP1
SCHEMBL7870619 0.95 MMP2 (1.00) MMP9MMP2MMP3MMP13MMP1
SCHEMBL6800772 0.91 MMP2 (0.77) MMP9MMP2MMP3MMP13MMP1
SCHEMBL8446281 0.91 MMP9 (1.00) MMP9MMP2MMP3MMP13MMP1
SCHEMBL6302637 0.89 MMP9 (0.73) MMP9MMP2MMP3MMP13MMP1
SCHEMBL21538657 0.89 MMP9 (0.73) MMP9MMP2MMP3MMP13MMP1
SCHEMBL6296214 0.89 MMP9 (0.73) MMP9MMP2MMP3MMP13MMP1
SCHEMBL27485402 0.88 MMP2 (0.80) MMP9MMP2MMP3MMP13MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250084077-A1 ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS ASTEX THERAPEUTICS LIMITED (GB) 2025-03-13 — — US disclosed
US-12091409-B2 Ether linked triazoles as NRF2 activators ASTEX THERAPEUTICS LIMITED (GB) 2024-09-17 — — US disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 — — EP disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 — — US disclosed
WO-2023075435-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE 주식회사 베르티스 2023-05-04 — — WO disclosed
US-11440882-B2 Process for the preparation of dexmethyl phenidate hydrochloride HARMAN FINOCHEM LIMITED (IN) 2022-09-13 — — US disclosed
US-20220283131-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS CO., LTD. (KR) 2022-09-08 — — US disclosed
US-20220089590-A1 ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS ASTEX THERAPEUTICS LIMITED (GB) 2022-03-24 — — US disclosed
WO-2022050529-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE ㈜베르티스 2022-03-10 — — WO disclosed
US-20210024461-A1 (S)-CSA Salt Of S-Ketamine, (R)-CSA Salt Of S-Ketamine And Processes For The Preparation Of S-Ketamine JANSSEN PHARMACEUTICA NV (BE) 2021-01-28 — — US disclosed
WO-2000061542-A1 CASPASE INHIBITORS AND THE USE THEREOF CYTOVIA, INC. (US) 2000-10-19 — — WO disclosed
US-5753652-A Antiretroviral hydrazine derivatives NOVARTIS CORPORATION (US) 1998-05-19 — — US disclosed
EP-0839798-A2 Intermediates for preparating non-peptide retroviral protease inhibitors ABBOTT LABORATORIES (US) 1998-05-06 — — EP disclosed
EP-0808824-A2 Process for preparing optically active 2-halogeno-3-hydroxypropionic acid ester TANABE SEIYAKU CO., LTD. (JP) 1997-11-26 — — EP disclosed
US-5670675-A Retroviral protease inhibiting compounds ABBOTT LABORATORIES (US) 1997-09-23 — — US disclosed
EP-0521827-B1 Pharmacological active hydrazin derivatives and process for their preparation CIBA GEIGY AG (CH) 1996-09-25 — — EP disclosed
US-5545750-A TREATING HUMAN IMMUNODEFICIENCY VIRUS ABBOTT LABORATORIES (US) 1996-08-13 — — US disclosed
EP-0521827-A1 Pharmacological active hydrazin derivatives and process for their preparation CIBA-GEIGY AG (CH) 1993-01-07 — — EP disclosed
US-5142056-A Human immunodeficiency virus protease inhibitor ABBOTT LABORATORIES (US) 1992-08-25 — — US disclosed
EP-0402646-A1 Retroviral protease inhibiting compounds ABBOTT LABORATORIES (US) 1990-12-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024461-A1 (S)-CSA Salt Of S-Ketamine, (R)-CSA Salt Of S-Ketamine And Processes For The Preparation Of S-Ketamine STS, SRR, SRM MMP9 4272/4885MMP2 4501/4885MMP3 3620/4885
US-20220089590-A1 ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS NFE2L2, KEAP1, NQO1 MMP9 4649/4885MMP2 4535/4885MMP3 4397/4885
US-20250084077-A1 ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS NFE2L2, KEAP1, NQO1 MMP9 4649/4885MMP2 4535/4885MMP3 4397/4885
US-12091409-B2 Ether linked triazoles as NRF2 activators NFE2L2, KEAP1, NQO1 MMP9 4649/4885MMP2 4535/4885MMP3 4397/4885
US-11440882-B2 Process for the preparation of dexmethyl phenidate hydrochloride SLC6A3, COMT, DAO MMP9 1184/4885MMP2 695/4885MMP3 1303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.